Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation
Open Access
- 5 February 2011
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 24 (5) , 451-460
Abstract
The advent of novel immunosuppressive strategies in renal transplantation, with immunomodulatory properties, might facilitate long‐term allograft survival. T‐cell depletion, costimulation‐blockade and mTor inhibition have been shown to favour anti‐donor hyporesponsiveness. Recently, the combination of rATG, belatacept (Bela) and sirolimus (SRL) has been used in kidney transplantation, showing very low incidence of acute rejection and excellent 12‐month graft and patient survival. Herein, we have analysed the 1‐year evolution of memory/effector and regulatory T cells and assessed the donor‐specific T‐cell alloimmune response in a group of these patients and compared with others treated with a calcineurin‐inhibitor(CNI)‐based (rATG/tacrolimus/MMF), and two other Bela‐based regimens (rATG/Bela/MMF and basiliximab/Bela/MMF/steroids). During the first year after transplantation, patients receiving rATG/Bela/SRL had significantly higher percentage of Tregs upon the memory T‐cell compartment and showed a potent anti‐donor suppressive activity. In an in vitro naive and memory/effector T‐cell co‐culture, the combination of costimulation‐blockade and SRL could abrogate both antigen‐specific T‐cell responses as efficiently as using a CNI drug. The combination of T‐cell depletion, costimulation‐blockade and mTor inhibition seems to be able to allow Treg survival and inhibit donor‐specific alloreactive effector immune responses after kidney transplantation in humans.Keywords
This publication has 19 references indexed in Scilit:
- Immunosuppression with Belatacept-Based, Corticosteroid-Avoiding Regimens in De Novo Kidney Transplant RecipientsAmerican Journal of Transplantation, 2010
- Presence of FoxP3+ Regulatory T Cells Predicts Outcome of Subclinical Rejection of Renal AllograftsJournal of the American Society of Nephrology, 2008
- The Effect of Costimulatory and Interleukin 2 Receptor Blockade on Regulatory T Cells in Renal TransplantationAmerican Journal of Transplantation, 2008
- Costimulation blockade in autoimmunity and transplantationJournal of Allergy and Clinical Immunology, 2008
- Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytesNature Medicine, 2007
- Achieving Donor-Specific Hyporesponsiveness Is Associated with FOXP3+ Regulatory T Cell Recruitment in Human Renal Allograft InfiltratesThe Journal of Immunology, 2007
- Regulatory T Cells and T Cell DepletionJournal of the American Society of Nephrology, 2007
- Costimulation Blockade with Belatacept in Renal TransplantationNew England Journal of Medicine, 2005
- CTLA-4Ig is Finally Making It: A Personal PerspectiveAmerican Journal of Transplantation, 2005
- Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T CellsThe Journal of Immunology, 2003